The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index.
ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia
Abstract
Key Points: High levels of the anti-apoptotic factor BCL-2 can be therapeutically exploited by the BH3 mimetic ABT-199 in human T-ALL.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, ABT-199 caused less damage to platelets than the second-generation drug ABT-263 in both in vitro and in vivo studies.362–364”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [362]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
The Bcl-2 apoptotic switch in cancer development and therapy
Adams, J. M., & Cory, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210220 · Cited by 2,256
Reich, M. M., Liefeld, T., Gould, J., Lerner, J., Tamayo, P., & Mesirov, J. P. (2006) · Nature Genetics · doi:10.1038/ng0506-500 · Cited by 2,053
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Pui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia
Ferrando, A. A., Neuberg, D. S., Staunton, J. E., Loh, M. L., Huard, C., Raimondi, S. C., Behm, F. G., Pui, C., Downing, J. R., Gilliland, D. G., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00018-1 · Cited by 1,130
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia
Coustan‐Smith, E., Mullighan, C. G., Onciu, M. M., Behm, F. G., Raimondi, S. C., Pei, D., Cheng, C., Su, X., Rubnitz, J. E., Basso, G., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70314-0 · Cited by 1,012
Roberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S., Huang, D. C. S., Xiong, H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 855
Cited by
Sorted by citations
Items 201–266 of 266
Lymphoid Malignancies in Ataxia–Telangiectasia: Experience with Novel Targeted Therapies
Catueno, S., Ramakrishnan, R., Elitzur, S., Garcia, M. B., McCall, D. C., Núnêz, C., Roth, M. E., Ferrajoli, A., Cuglievan, B., & Gibson, A. (2025) · Pediatric Blood & Cancer · doi:10.1002/pbc.31885 · Cited by 2
Mi, R., Guo, S., Yang, W., Wang, L., Ma, Y., Chen, L., Li, D., & Wei, X. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1693061 · Cited by 2
Stewart, M. L., Gibbs, J., Watanabe‐Smith, K., Nguyen, A. H., Kenna, I., Thiel-Klare, K., Kaempf, A. J., Bottomly, D., Kurtz, S. E., Eide, C. A., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102526 · Cited by 3
Ward, A. C. (2026) · Biomolecules · doi:10.3390/biom16020219 · Cited by 3
Gong, X., Liu, Y., Fang, Q., Gu, R., Liu, K., Lin, D., Zhou, C., Zhang, G., Gong, B., Wei, S., et al. (2026) · Blood · doi:10.1182/blood.2026033577 · Cited by 2
Pagliaro, L., Rosati, R., Giaimo, M., Bardelli, V., Zamponi, R., Tragni, K., Montanaro, A., Gherli, A., Messina, M., Piciocchi, A., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01645-1 · Cited by 2
Anlotinib exerts an anti-T-cell acute lymphoblastic leukemia effect in vitro and in vivo
Zhang, X., Geng, L., Yang, L. C., Wang, Y., Zou, Z., Zhang, Y., Xu, H., Lei, H., Cao, Y., Wu, Y., et al. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110837 · Cited by 2
Shiomi, I., Nakako, S., Nakane, T., Ogawa, Y., Araki, T., Fujitani, Y., Yamamura, R., Hino, M., & Nakamae, H. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03678-9 · Cited by 2
UNC119 regulates T-cell receptor signalling in primary T cells and T acute lymphocytic leukaemia
Samarakoon, Y., Yelland, T., Garcia-Gonzalez, E., Justo-Júnior, A. D. S., Mahmood, M., Manoharan, A., Patterson, S. D., Serafin, V., Gammage, P. A., Marmiroli, S., et al. (2025) · Life Science Alliance · doi:10.26508/lsa.202403066 · Cited by 2
Agrawal, V., Arslan, S., Pourhassan, H., Koller, P., Aldoss, I. T., & Pullarkat, V. A. (2025) · British Journal of Haematology · doi:10.1111/bjh.20065 · Cited by 2
Navigating the nexus of MRD and novel agents in ALL
Advani, A. S., & Copelan, E. A. (2019) · Hematology · doi:10.1182/hematology.2019000008 · Cited by 2
Thomas, X., & Jeune, C. L. (2016) · EMJ Hematology · doi:10.33590/emjhematol/10312198 · Cited by 2
Gigliotti, F., Brescia, C., Audia, S., Cantafio, M. E. G., Malatesta, P., Bellisario, M.-L., Torcasio, R., Cantaffa, R., Galea, E., Iuliano, R., et al. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10979-1 · Cited by 1
Hu, H., Zhao, H., Lu, P., Ma, T., Yoshimura, S., Karol, S. E., Pui, C., Teachey, D. T., Yang, J. J., Ng, A. H. C., et al. (2026) · Med · doi:10.1016/j.medj.2025.100966 · Cited by 1
Tsunemine, H., & Takahashi, T. (2015) · InTech eBooks · doi:10.5772/60901 · Cited by 1
Gavrilina, O. A., Сергеевна, К. Е., Parovichnikova, E. N., Troitskaya, V. V., Sokolov, A. N., Baskhaeva, G. A., Zarubina, K. I., Таймуразовна, Ф. З., Kuzmina, L. A., Николаевна, Д. В., et al. (2019) · Гематология и трансфузиология · doi:10.35754/0234-5730-2019-64-4-382-395 · Cited by 1
Genomics and precision medicine in pediatric acute lymphoblastic leukemia
Santiago, R., & Tran, T. H. (2021) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2021.16 · Cited by 1
Peng, L., Wang, S., Guo, S., Zhang, J., Liu, Y., Rousseaux, S., Khochbin, S., Chen, B., Wang, J., & Mi, J. (2022) · Immunobiology · doi:10.1016/j.imbio.2022.152205 · Cited by 1
The Therapeutic Values of IL-7/IL-7R and the Recombinant Derivatives in Glioma: A Narrative Review
Hesari, M., Attar, Z., Soltani-Shirazi, S., Keshavarzian, O., Taheri, R., Tabrizi, R., & Fouladseresht, H. (2023) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2023.0050 · Cited by 1
Modulation of Autophagy and Apoptosis in Leukemia
Torre, L. D., Beato, A., Capone, V., Carannante, D., Verrilli, G., Favale, G., Taherigorji, H., Naseer, M., Altucci, L., Benedetti, R., et al. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00039-1 · Cited by 1
Tari, K., Nasimian, A., Kazi, J. U., & Abroun, S. (2023) · PubMed Central · doi:10.22088/ijmcm.bums.12.3.229 · Cited by 1
Li, J., Ye, C., Li, H., & Li, J. (2025) · Cancer Biology & Therapy · doi:10.1080/15384047.2025.2457777 · Cited by 1
Thomas, X. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00339-1 · Cited by 1
Childhood Acute Lymphoblastic Leukemia: How to Cure the Very High Risk?
Pui, C. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.07.396 · Cited by 1
Hosseini, M. S., Jafari, L., Yami, A., & Gharehbaghian, A. (2022) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_567_19 · Cited by 1
New Agents for the Treatment of T-Cell Acute Lymphoblastic Leukemia
Raikar, S. S., Teachey, D. T., & Gossai, N. P. (2022) · Springer eBooks · doi:10.1007/978-3-030-85147-7_14
van der Zwet, J. C. G. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1098
Data from Deletion 6q Drives T-cell Leukemia Progression by Ribosome Modulation
Gachet, S., El-Chaar, T., Avran, D., Genescà, E., Catez, F., Quentin, S., Delord, M., Thérizols, G., Briot, D., Meunier, G., et al. (2023) · doi:10.1158/2159-8290.c.6546977.v1
Self-citationNovel Biomarkers and Molecular Targets in ALL
De, H., & Leonard, J. T. (2023) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-023-00718-3
Chidamide and venetoclax synergistically regulate the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL
Zhao, L., Sun, L., Kong, D., Cao, R., Guo, Z., Guo, D., Li, Q., Hao, J., Li, Y., & Emails, L. (2024) · Annals of Hematology · doi:10.1007/s00277-024-06110-2
Bautista, F. J., Zwaan, C. M., & Lissat, A. (2024) · Pediatric oncology · doi:10.1007/978-3-031-71180-0_23
A tumor suppressor role of the miR-15b/16-2 cluster in T-cell acute lymphoblastic leukemiaPreprint
González-García, S., García-León, M. J., García-Peydró, M., Fuentes, P., Alcaín, J., Martín‐Gayo, E., Croce, C. M., Garzon, R., & Toribio, M. L. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.07.663472
Li, D., Yuan, Y., Meng, C., Lin, Z., Zhao, M., Shi, L., Li, M., Ye, D., Yue, C., He, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26697824
Li, D., Yuan, Y., Meng, C., Lin¹, Z., Zhao, M., Shi, L., Li, M., Ye, D., Yue, C., He, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26697827
Li, D., Yuan, Y., Meng, C., Lin, Z., Zhao, M., Shi, L., Li, M., Ye, D., Yue, C., He, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25478778
Li, D., Yuan, Y., Meng, C., Lin, Z., Zhao, M., Shi, L., Li, M., Ye, D., Yue, C., He, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26697818
Li, D., Yuan, Y., Meng, C., Lin, Z., Zhao, M., Shi, L., Li, M., Ye, D., Yue, C., He, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26697839
Li, D., Yuan, Y., Meng, C., Lin, Z., Zhao, M., Shi, L., Li, M., Ye, D., Yue, C., He, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25479136
Li, D., Yuan, Y., Meng, C., Lin, Z., Zhao, M., Shi, L., Li, M., Ye, D., Yue, C., He, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26697842
Li, D., Yuan, Y., Meng, C., Lin, Z., Zhao, M., Shi, L., Li, M., Ye, D., Yue, C., He, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26697830
Li, D., Yuan, Y., Meng, C., Lin, Z., Zhao, M., Shi, L., Li, M., Ye, D., Yue, C., He, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26697833
Li, D., Yuan, Y., Meng, C., Lin¹, Z., Zhao, M., Shi, L., Li, M., Ye, D., Yue, C., He, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26697851
Li, D., Yuan, Y., Meng, C., Lin, Z., Zhao, M., Shi, L., Li, M., Ye, D., Yue, C., He, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26697845
Li, D., Yuan, Y., Meng, C., Lin, Z., Zhao, M., Shi, L., Li, M., Ye, D., Yue, C., He, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26697836
Li, D., Yuan, Y., Meng, C., Lin, Z., Zhao, M., Shi, L., Li, M., Ye, D., Yue, C., He, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26697821
Li, D., Yuan, Y., Meng, C., Lin, Z., Zhao, M., Shi, L., Li, M., Ye, D., Yue, C., He, X., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26697848
The use of venetoclax in the treatment of acute lymphoblastic leukemia—a systematic review
Kowalczyk, A., Zarychta, J., Zawitkowska, J., & Lejman, M. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251403912
Kaya, S. Y., Maral, S., Abedi, A. H., Beköz, H. S., & Kaynar, L. (2026) · Journal of Health Sciences and Medicine · doi:10.32322/jhsm.1825832
Assaf, S., Sarig, O., Ishtewy, R., Zoabi, Y., Feller, Y., Malovitski, K., Mohamad, J., Bergson, S., Bilu, C., Shoshan‐Barmatz, V., et al. (2025) · Skin Health and Disease · doi:10.1093/skinhd/vzaf107
Rankin, A. W., Keating, A. K., Abu‐Arja, R., Thakar, M. S., & Rangarajan, H. G. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201141
Recent advance in the targeted protein degradation technology for overcoming acute leukemia
Jin, X., Shi, Z., Liang, Z., Chen, J., Wang, C., Lou, Y., Cao, X., Zhu, L., Zhao, Y., Zhao, C., et al. (2026) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2026.100331
Caractérisation et études précliniques d'un nouvel inhibiteur naturel de MCL-1
Daressy, F. (2020) · theses.fr (ABES) · doi:10.70675/4e4153f4zba2dz49bcz9862z38251f3f7882
Bcl2L10 : polymorphisme, résistance oncogénique et conséquences thérapeutique dans le cancer du sein
Quang, D. M. (2021) · theses.fr (ABES) · doi:10.70675/86dd7fafzcb40z4cedz8eb7zbb41268cd809
The advancement of Venetoclax in hematological malignancies and solid tumors
Long, C., Zhang, H., Yao, Y., Liu, T., Peng, H., & Sheng, Y. (2026) · Heliyon · doi:10.1016/j.heliyon.2026.e45207
Kumar, A., Hamane, K., Duault, C., Lima-Júnior, J. R., Jung, D. H., Qin, H., Salcido, S., Huang, M., Guo, X., Khani, A. T., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102945
Chen, G., Min, C., Xu, J., Zheng, J., Li, H., & Li, Z. (2026) · Annals of Hematology · doi:10.1007/s00277-026-07190-y
Lei, Y., Zhao, X., Huang, H., Duan, L., Xu, J., Miao, K., Zhao, H., Qiao, C., Hong, M., Qian, S., et al. (2026) · Therapeutic Advances in Hematology · doi:10.1177/20406207261480378
BindingDB Entry 50013495: Dual Bcl-X
BindingDB (2022) · UC San Diego · doi:10.7270/q2t157dk
Metadata
- Authors
- Peirs, S., Matthijssens, F., Goossens, S., Van de Walle, I., Ruggero, K., de Bock, C. E., Degryse, S., Canté-Barrett, K., Briot, D., Clappier, E., Lammens, T., De Moerloose, B., Benoit, Y., Poppe, B., Meijerink, J. P., Cools, J., Soulier, J., Rabbitts, T. H., Taghon, T., Speleman, F., & Van Vlierberghe, P.
- Affiliations
- Center for Medical Genetics,
- Vlaams Instituut voor Biotechnologie (BE)
- Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium;
- John Radcliffe Hospital (GB)
- Laboratory for the Molecular Biology of Leukemia, Center for Human Genetics, University of Leuven and Center for the Biology of Disease, Vlaams Instituut voor Biotechnologie, Leuven, Belgium;
- Erasmus MC (NL)
- Inserm (FR)
- Ghent University Hospital (BE)
- Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium
- Ghent University (BE)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2014-12-11
- Volume
- 124
- Issue
- 25
- Pages
- 3738-3747
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2048591984
- Cited by
- 264
- References
- 44
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 31 · 2023: 29 · 2022: 24 · 2021: 25 · 2020: 22 · 2019: 25 · 2018: 22 · 2017: 18 · 2016: 22 · 2015: 16
- FWCI
- 18.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Funders
- European Hematology Association (TRTH104)
- Wellcome Trust (099246/Z/12/Z)
- Agence Nationale de la Recherche (ANR-10-IBHU-0002)
- Topics
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- venetoclax, BCL-2 inhibition, BH3 mimetics, T-cell acute lymphoblastic leukemia, drug synergy, doxorubicin, L-asparaginase, dexamethasone, TLX3, HOXA, TAL1, molecular subtypes, treatment resistance
- MeSH terms
- Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Cell Survival, Cells, Cultured, Child, Drug Synergism, Humans, Sulfonamides, Tumor Cells, Cultured, Blotting, Western, Gene Expression Regulation, Leukemic, Survival Analysis, Mice, SCID, Mice, Inbred NOD, Bridged Bicyclo Compounds, Heterocyclic, Jurkat Cells, Proto-Oncogene Proteins c-bcl-2, Inhibitory Concentration 50, Reverse Transcriptase Polymerase Chain Reaction, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Xenograft Model Antitumor Assays, Cell Line, Tumor, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
